GSK Doubles Cancer Drug Trials to Navigate Patent Cliff and Rebuild Oncology Portfolio
GSK expects to nearly double the number of cancer medicines it is testing in clinical trials next year, a move driven by the need to replace revenue from blockbuster HIV drugs facing patent expirations.
This strategic expansion comes as the British pharmaceutical giant looks to rebuild its oncology portfolio after exiting the space more than a decade ago. The push represents a significant shift for a company currently valued at $122.6 billion, aiming to secure its long-term earnings while offering new hope for patients seeking advanced treatments.
A Strategic Pivot Away from HIV Blockbusters
The decision to accelerate cancer drug development is directly linked to the looming patent cliff for GSK’s HIV revenue streams. According to a report by the Wall Street Journal, CEO Luke Miels is behind an effort to reassure investors that the company can navigate this financial transition successfully.
In July 2026, GSK stated it expected to have more than 20 late-stage studies underway by the end of that year. Of the seven drugs identified for faster development at that time, three were specifically cancer medicines. This indicates a clear prioritization of oncology assets to ensure sustained growth as older products lose their exclusivity protections.
The company currently holds a clinical-stage portfolio consisting of about 15 assets. By 2027, this number is likely to increase to 19 or 20 late-stage oncology studies. This rapid scaling demonstrates a commitment to moving candidates from early-stage research directly into later phases to speed up the path to market.
The Human Side of Pipeline Expansion
Hesham Abdullah, GSK’s head of oncology research and development, told the Wall Street Journal that drug candidates will be moved straight from early-stage to late-stage studies. This approach aims to reduce the time patients wait for potential new therapies to reach hospital pharmacies.
For families affected by cancer, this acceleration means faster access to treatments that could offer a second line of defense when standard options run out. The human side of this strategy involves getting promising molecules into trials where they can be tested on real people sooner rather than later.
Cancer drugs such as ris-rez and mo-rez are at the centre of GSK’s current strategy. These specific compounds represent a return to a field the company left over ten years ago, signaling a renewed focus on diseases that impact millions globally. The goal is not just to add numbers to a pipeline but to create meaningful options for those living with the disease.
Financial Stakes and Historical Context
The financial pressure behind this expansion is clear: GSK’s oncology segment contributed £1.08 billion ($1.44 billion) in the first half of 2026 alone. This revenue stream has become increasingly critical as the company transitions away from its HIV dominance.
Historically, pharmaceutical companies rely on a steady pipeline to maintain stock value when patents expire. GSK’s current trajectory shows an aggressive response to this economic reality. By doubling their trial capacity, they are betting that these new assets will generate enough future revenue to offset the decline in HIV drug sales.
What This Means for Patients and Investors
For investors, expanding a pipeline into clinical trials impacts long-term stock value by diversifying revenue sources and mitigating the risk of patent cliffs. However, it also increases research investment priorities significantly, requiring substantial capital to run more simultaneous studies.
For patients, what this means is that there are more potential treatments in development today than there were a decade ago. The move suggests GSK is willing to take calculated risks to bring new options to market, even if the path from early-stage discovery to late-stage study is compressed.
It is important to remember that having a drug in a clinical trial does not guarantee approval. Early-phase results often show promise, but later phases can reveal side effects or lack of efficacy that halt development. Furthermore, these figures reflect potential future outcomes; they do not yet show survival data or long-term remission rates for specific patients.
The goal remains to provide real talk and facts, not hype. While the expansion is a positive sign for the industry’s capacity to innovate, every patient’s journey is unique. If you or a loved one are considering new treatment options, always talk to your doctor or oncologist to discuss what these trials might mean for your specific situation.
Regulatory Milestones and Viral Treatments
Beyond cancer, GSK has secured a major victory with the US Food and Drug Administration (FDA) approval of Hibsago (bepirovirsen) for chronic hepatitis B in October 2026. This first-in-class antisense oligonucleotide offers unprecedented functional cure rates compared to standard care, marking a significant expansion into viral therapies distinct from its oncology push.
The approval was granted under FDA Priority Review and Breakthrough Therapy Designation, recognizing the drug’s potential to transform management of the disease. According to GSK, this treatment allows for a six-month course with an option for self-administration after the first dose, addressing the needs of the approximately 1.7 million people affected by chronic hepatitis B in the US.
Tony Wood, Chief Scientific Officer at GSK, stated that despite current therapies, many patients remain on indefinite treatment facing serious liver complications. With Hibsago, patients now have the potential to achieve a functional cure after a short period, a long-standing goal for both patients and physicians. This development underscores GSK’s broad portfolio strategy, leveraging its history of creating essential medicines like amoxicillin and zidovudine while addressing new public health challenges.
The success of Hibsago complements the oncology expansion reported in late October 2026. While the cancer pipeline aims to replace revenue from HIV drugs facing patent expirations, the hepatitis B approval demonstrates GSK’s ability to innovate across different therapeutic areas. This dual approach ensures sustained growth as older products lose exclusivity protections, providing new hope for patients seeking advanced treatments regardless of their specific condition.
Sources
- GSK plc
- Hibsago (bepirovirsen) approved in the US for the treatment of chronic hepatitis B (CHB) | GSK US
- GSK to nearly double cancer drugs in trials next year, WSJ reports
Photo: National Cancer Institute / Unsplash (Unsplash License)
